Compare

Natural Alternatives International Inc vs Cronos Group Inc. vs Niagen Bioscience, Inc. vs biote Corp.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearNatural Alternatives International Inc
NAII
Cronos Group Inc.
CRON
Niagen Bioscience, Inc.
NAGE
biote Corp.
BTMD
Year ended2026-06-302025-12-312025-12-312025-12-31
Revenue$142.51M$146.59M$129.42M$192.22M
Revenue growth (YoY)+9.7%+24.6%+29.9%-2.5%
Gross margin6.3%42.8%64.3%n/a
Operating margin-13.2%-11.9%12.6%18.5%
Net margin-14.5%-6.4%13.4%14.1%
Net income-$20.70M-$9.45M$17.38M$27.05M
EPS (Diluted)-$3.43-$0.02$0.20$0.74
Operating cash flow-$8.92M$25.87M$13.50M$35.19M
Free cash flow-$12.62M$149.0Kn/a$30.18M
Cash & equivalents$7.39M$791.79Mn/a$24.12M
Total assets$126.45M$1.20B$106.41M$107.61M
Total liabilities$76.49M$54.18M$29.87M$158.01M
Shareholders' equity$49.96M$1.14B$76.53M-$58.54M
Return on year-end equity-41.4%-0.8%22.7%n/a
Shares outstanding6.27M381.59M79.71Mn/a

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearNatural Alternatives International IncCronos Group Inc.Niagen Bioscience, Inc.biote Corp.
Latest$142.51M
Ended 2026-06-30
$146.59M
Ended 2025-12-31
$129.42M
Ended 2025-12-31
$192.22M
Ended 2025-12-31
1 year earlier$129.86M
Ended 2025-06-30
$117.61M
Ended 2024-12-31
$99.60M
Ended 2024-12-31
$197.19M
Ended 2024-12-31
2 years earlier$113.80M
Ended 2024-06-30
$87.24M
Ended 2023-12-31
$83.57M
Ended 2023-12-31
$185.36M
Ended 2023-12-31
3 years earlier$154.01M
Ended 2023-06-30
$86.75M
Ended 2022-12-31
$72.05M
Ended 2022-12-31
$164.96M
Ended 2022-12-31
4 years earlier$170.97M
Ended 2022-06-30
$64.56M
Ended 2021-12-31
$67.45M
Ended 2021-12-31
$139.40M
Ended 2021-12-31